NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
Clinical Trials
15 trialsNCT05388877 2025-08-19
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Mayo Clinic
Phase 1 Terminated
NCT03026517 2025-01-23
Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02097225 2024-10-16
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03272464 2023-09-22
INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.
Massachusetts General Hospital
Phase 1 Terminated
NCT03332589 2022-05-20
E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)
Spirita Oncology, LLC
Phase 1 Terminated
NCT01940809 2022-03-10
Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT02110355 2021-03-26
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Kartos Therapeutics, Inc.
Phase 1 Completed
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown
NCT02027961 2019-05-17
Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone
MedImmune LLC
Phase 1 Completed
NCT02447939 2018-09-14
Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma
GlaxoSmithKline
Phase 1 Withdrawn
NCT02915666 2018-05-15
A Clinical Trial of Patients With Melanoma
University of Texas Southwestern Medical Center
Phase 1 Withdrawn
NCT01767454 2017-11-14
Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
GlaxoSmithKline
Phase 1 Completed
NCT02082665 2017-07-24
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
GlaxoSmithKline
Phase 1 Completed
NCT02357732 2015-12-11
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
University of Pittsburgh
Phase 1 Withdrawn